论文部分内容阅读
Aim: Cancer immunotherapy has flourished in recent years, however, clinical studies about immunotherapy in combination with chemotherapy, which are still in their infancy, have not achieved a clear and definite consensus on their clinical benefits.Our aim was to investigate whether autologous dendritic cell-cytokine-induced killer cell (DCCIK) immunotherapy could improve the therapeutic benefits of chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC).Methods: A literature search was electronically conducted in PubMed, the Cochrane Central Register of Controlled Trials, CNKI and Wanfang Database for randomized controlled trials (RCTs), and relevant references were also retrieved.